Axonics receives regulatory approval for rechargeable SNM System in Australia

Written by Emily J. Thompson, Senior Investment Analyst

AXNX%

Updated: Sep 26 2024

0mins

Regulatory Approval: Axonics has received approval from the Therapeutic Goods Administration to market the R20 rechargeable sacral neuromodulation system in Australia for treating overactive bladder and fecal incontinence in adults.
Product Features and Launch: The R20 neurostimulator boasts a functional life of at least 20 years, requires recharging every 6 to 10 months, and will be available for sale in Australia starting November.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Axonics receives regulatory approval for rechargeable SNM System in Australia

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

S&P 500 Tech Sector XLK Rises 25.24%, Outpacing Broader Market by 16.72%

Salesforce (CRM) Partners with Mr. Beast for Super Bowl Ad

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch